Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626717 | 0.81 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL5103136 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL24901912 | 0.79 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL3542516 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL23447728 | 0.77 | ADORA3 (0.64) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL23413556 | 0.75 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BALDH1A1ADORA3 | |
| SCHEMBL30153455 | 0.72 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL9428047 | 0.70 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL23447725 | 0.70 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BKDM4EALDH1A1 | |
| SCHEMBL24901914 | 0.70 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BALDH1A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | ADORA2A, ADORA2B, ENTPD5 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.